MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

M7T

M7T - MACH7 TECHNOLOGIES LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.45
Index:

Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.375

27 May
2025

-0.010

OPEN

$0.38

-2.60%

HIGH

$0.38

165,262

LOW

$0.38

TARGET
$1.37 265.3% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
M7T: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 3.3 - 2.0 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-3.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx29.1 M
Book Value Per Share xxxxxxxxxxxxxxx21.5
Net Operating Cash Flow xxxxxxxxxxxxxxx3.5 M
Net Profit Margin xxxxxxxxxxxxxxx-27.38 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-14.32 %
Return on Invested Capital xxxxxxxxxxxxxxx-14.05 %
Return on Assets xxxxxxxxxxxxxxx-10.26 %
Return on Equity xxxxxxxxxxxxxxx-14.32 %
Return on Total Capital xxxxxxxxxxxxxxx-17.73 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx26 M
Price To Book Value xxxxxxxxxxxxxxx2.98

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxxxxx1.34 %
Cost of Goods Sold xxxxxxxxxxxxxxx33 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

06/05/2025

1

Add

$1.37

265.33%

Morgans views the latest quarterly report from Mach7 Technologies as mixed due to a slight shrinkage in subscription value and no new contract wins of note.

Delays with the Veterans Affairs contract have weighed on the company's year-to-date performance, the broker emphasises. Organic growth and upgrades from existing customers are offering some revenue support.

Management retained FY25 guidance of 15% to 25% growth in compound average recurring revenue, and Morgans notes the company has boosted transaction contract revenue by $5.1m over the quarter.

No change to the analyst's earnings estimates. Add rating with $1.37 target retained.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.00 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.40 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

01/05/2025

1

Overweight

$0.85

126.67%

Mach7 Technologies reported a $24.4m annual recurring revenue (ARR) run rate and $30.8m contracted ARR, both slightly below the Wilsons' forecasts, while operating cash flow of $2.6m marked the second consecutive positive quarter.

Total contract value for the quarter was $5.1m, driven primarily by renewals, with no new customer wins reported, observes the broker.

Management reiterated FY25 guidance of 15-25% year-on-year growth in ARR and contracted ARR, though fourth-quarter wins are required to meet targets, cautions the analyst.

Veterans Affairs implementation, once expected in mid-2024, may now slip to FY26, reducing the broker's FY26 and FY27 forecasts.

Wilsons lowers the target price to 85c from $1.00 and retains an Overweight rating.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.70 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

M7T STOCK CHART

FNArena News on M7T

1
Australian Broker Call *Extra* Edition – May 01, 2025

May 01 2025 - Daily Market Reports
2
FNArena Corporate Results Monitor – 28-02-2025

Feb 28 2025 - Australia
3
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
4
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View
5
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View

Latest Healthcare services News

1
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
2
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
3
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
4
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
5
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
6
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
7
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
8
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
9
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
10
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps